This is a routine annual filing with no new material information. Traders should focus on the Q4 FY2026 earnings call transcript (filed May 18, 2026) for any operational updates. The 20-F itself provides no immediate trading catalyst.
Price Chart
Executive Summary
Dr. Reddy's filed its annual Form 20-F for the fiscal year ended March 31, 2026, a routine annual report with no new material financial disclosures beyond what was previously reported in its Q4 FY2026 earnings. The filing confirms 834,656,970 equity shares outstanding and the company's status as a large accelerated filer. No material changes, restatements, or going-concern issues are noted.
Key Facts
- Annual report for fiscal year ended March 31, 2026, filed on Form 20-F
- 834,656,970 equity shares outstanding as of March 31, 2026
- Company confirms it is a large accelerated filer and has filed all required reports
- No restatements, error corrections, or going-concern issues disclosed
- Financial statements prepared under IFRS as issued by IASB
- Convenience translation rate: US$1 = Rs. 93.83 as of March 31, 2026
Financial Impact
No new financial figures disclosed in this filing beyond previously reported Q4 FY2026 results
Risk Factors
- Risk factors disclosed include pricing pressure, regulatory inspections, patent litigation, and geopolitical instability in Russia/Ukraine and Middle East
- U.S. FDA issued a complete response letter for biosimilar rituximab BLA in November 2024; additional response submitted February 2026 with no approval timeline certainty
- Potential impact from U.S. executive order on most-favored-nation drug pricing (May 12, 2025) remains uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001575872-26-000381 |
| Document: 0001575872-26-000381-index.html | 0001575872-26-000381 |
| Document: 0001575872-26-000381.txt | 0001575872-26-000381 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $11.91 $11.55 | ▼ −3.02% | ▼ −2.56% | $12.25 (+2.85%) |
Sep 10, 2026 22d ago | 6-K | $11.71 $11.90 | ▲ +1.62% | ▲ +0.77% | $12.25 (+4.61%) |
Sep 10, 2026 22d ago | 6-K | $11.71 $11.90 | ▲ +1.62% | ▲ +0.77% | $12.25 (+4.61%) |
Aug 26, 2026 5w ago | 6-K | $12.22 $12.16 | ▼ −0.49% | ▼ −1.15% | $12.25 (+0.25%) |
Aug 17, 2026 6w ago | 6-K | $12.11 $12.15 | ▲ +0.33% | ▲ +1.01% | $12.25 (+1.16%) |
Aug 13, 2026 7w ago | 6-K | $12.42 $12.27 | ▼ −1.21% | ▼ −1.01% | $12.25 (−1.37%) |
Aug 10, 2026 7w ago | 6-K | $12.15 $12.45 | ▲ +2.47% | ▲ +2.79% | $12.25 (+0.82%) |
Aug 3, 2026 8w ago | 6-K | $12.07 $12.10 | ▲ +0.25% | ▼ −1.55% | $12.25 (+1.49%) |
Jul 29, 2026 9w ago | 6-K | $11.76 $11.83 | ▲ +0.60% | ▼ −1.08% | $12.25 (+4.17%) |
Jul 23, 2026 10w ago | 6-K | $11.80 $11.79 | ▼ −0.08% | ▼ −0.19% | $12.25 (+3.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access